Search

Your search keyword '"Nishiyama, Takashi"' showing total 376 results
Start Over Author "Nishiyama, Takashi" Language english
376 results on '"Nishiyama, Takashi"'

1. Cover

Author

Nishiyama, Takashi

Published
2014

13. Notes

Author

Nishiyama, Takashi

Published
2014

17. Index

Author

Nishiyama, Takashi

Published
2014

20. Incidence and Risk Factors of Immediate Hypersensitivity Reactions and Immunization Stress-Related Responses With COVID-19 mRNA Vaccine

Author

Imai, Kazuo, Tanaka, Fumika, Kawano, Shuichi, Esaki, Kotoba, Arakawa, Junko, Nishiyama, Takashi, Seno, Soichiro, Hatanaka, Kosuke, Sugiura, Takao, Kodama, Yu, Yamada, Seigo, Iwamoto, Shinichiro, Takeshima, Shigeto, Abe, Nobujiro, Kamae, Chikako, Aono, Shigeaki, Ito, Toshimitsu, Yamamoto, Tetsuo, and Mizuguchi, Yasunori

Published
2022
Full Text
View/download PDF

24. Progress on the Synthesis of the Aromathecin Family of Compounds: An Overview.

Author

Nishiyama, Takashi, Mizuno, Shota, Hieda, Yuhzo, and Choshi, Tominari

Subjects
*FAMILIES, *MOIETIES (Chemistry), *PYRIDONE, *PYRROLIDINE, *PYRIDINE
Abstract

We present a systematic review of the methods developed for the synthesis of the aromathecin family of compounds (benz[6,7]indolizino[1,2-b]quinolin-11(13H)-ones) and their derivatives. These methods can be broadly classified into four categories based on the construction of pentacyclic structures: Category 1: by constructing a pyridone moiety (D-ring) on the pyrroloquinoline ring (A/B/C-ring), Category 2: by constructing a pyridine moiety (B-ring) on the pyrroloisoquinolone ring (C/D/E-ring), Category 3: by constructing an indolizidinone moiety (C/D-ring) in a tandem reaction, and Category 4: by constructing a pyrrolidine moiety (C-ring) on the isoquinolone ring (D/E-ring). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.

Author

Primadharsini, Putu Prathiwi, Nagashima, Shigeo, Nishiyama, Takashi, and Okamoto, Hiroaki

Subjects
HEPATITIS E virus, ANTIVIRAL agents, RIBAVIRIN, LIFE cycles (Biology), DRUG design, DRUG efficacy, CELL culture
Abstract

The hepatitis E virus (HEV) is increasingly acknowledged as the primary cause of acute hepatitis. While most HEV infections are self-limiting, cases of chronic infection and fulminant hepatitis necessitate the administration of anti-HEV medications. However, there is a lack of specific antiviral drugs designed for HEV, and the currently available drug (ribavirin) has been associated with significant adverse effects. The development of innovative antiviral drugs involves targeting distinct steps within the viral life cycle: the early step (attachment and internalization), middle step (translation and RNA replication), and late step (virus particle formation and virion release). We recently established three HEV reporter systems, each covering one or two of these steps. Using these reporter systems, we identified various potential drug candidates that target different steps of the HEV life cycle. Through rigorous in vitro testing using our robust cell culture system with the genotype 3 HEV strain (JE03-1760F/P10), we confirmed the efficacy of these drugs, when used alone or in combination with existing anti-HEV drugs. This underscores their significance in the quest for an effective anti-HEV treatment. In the present review, we discuss the development of the three reporter systems, their applications in drug screening, and their potential to advance our understanding of the incompletely elucidated HEV life cycle. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly

Author

Ohnishi, Takayuki, Yanazawa, Masako, Sasahara, Tomoya, Kitamura, Yasuki, Hiroaki, Hidekazu, Fukazawa, Yugo, Kii, Isao, Nishiyama, Takashi, Kakita, Akiyoshi, Takeda, Hiroyuki, Takeuchi, Akihide, Arai, Yoshie, Ito, Akane, Komura, Hitomi, Hirao, Hajime, Satomura, Kaori, Inoue, Masafumi, Muramatsu, Shin-ichi, Matsui, Ko, Tada, Mari, Sato, Michio, Saijo, Eri, Shigemitsu, Yoshiki, Sakai, Satoko, Umetsu, Yoshitaka, Goda, Natsuko, Takino, Naomi, Takahashi, Hitoshi, Hagiwara, Masatoshi, Sawasaki, Tatsuya, Iwasaki, Genji, Nakamura, Yu, Nabeshima, Yo-ichi, Teplow, David B., and Hoshi, Minako

Published
2015

49. Novel Approach to the Construction of Fused Indolizine Scaffolds: Synthesis of Rosettacin and the Aromathecin Family of Compounds.

Author

Mizuno, Shohta, Nishiyama, Takashi, Endo, Mai, Sakoguchi, Koharu, Yoshiura, Takaki, Bessho, Hana, Motoyashiki, Toshio, Hatae, Noriyuki, and Choshi, Tominari

Subjects
*CAMPTOTHECIN, *FAMILY structure, *MICROWAVE heating, *ACETIC anhydride, *FAMILIES, *ANTINEOPLASTIC agents
Abstract

Camptothecin-like compounds are actively employed as anticancer drugs in clinical treatments. The aromathecin family of compounds, which contains the same indazolidine core structure as the camptothecin family of compounds, is also expected to display promising anticancer activity. Therefore, the development of a suitable and scalable synthetic method of aromathecin synthesis is of great research interest. In this study, we report the development of a new synthetic approach for constructing the pentacyclic scaffold of the aromathecin family by forming the indolizidine moiety after synthesizing the isoquinolone moiety. Thermal cyclization of 2-alkynylbenzaldehyde oxime to the isoquinoline N-oxide, followed by a Reissert–Henze-type reaction, forms the key strategy in this isoquinolone synthesis. Under the optimum reaction conditions for the Reissert–Henze-type reaction step, microwave irradiation-assisted heating of the purified N-oxide in acetic anhydride at 50 °C reduced the formation of the 4-acetoxyisoquinoline byproduct to deliver the desired isoquinolone at a 73% yield after just 3.5 h. The eight-step sequence employed afforded rosettacin (simplest member of the aromathecin family) at a 23.8% overall yield. The synthesis of rosettacin analogs was achieved by applying the developed strategy and may be generally applicable to the production of other fused indolizidine compounds. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results